Skin barrier function improver
Patent Information
- Application Number
- JP2023142573
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-09-01
- Publication Date
- 2025-03-13
AI Technical Summary
【0031】 本発明によれば、コメの酵母発酵物と特定成分との組合せを有効成分とすることにより、作用効果に優れた皮膚バリア機能改善剤、フィラグリンmRNA発現促進剤、インボルクリンmRNA発現促進剤、ロリクリンmRNA発現促進剤、カリクレイン5 mRNA発現促進剤、カリクレイン7 mRNA発現促進剤、セリンペプチダーゼ阻害因子カザール5型(SPINK5)mRNA発現促進剤、カスパーゼ14 mRNA発現促進剤、ZO-1 mRNA発現促進剤、セマフォリン3A mRNA発現促進剤、表皮角化細胞増殖促進剤、およびサーチュイン1 mRNA発現促進剤を提供することができる。
Smart Images

Figure 2025035496000001 
Figure 2025035496000002 
Figure 2025035496000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a skin barrier function improving agent, and in particular to a skin barrier function improving agent containing a specific combination of ingredients derived from natural products as active ingredients. [Background technology]
[0002] The epidermis, which functions to mitigate external stimuli and control the loss of body components such as water, is composed of a four-layer structure starting from the basal layer at the bottom, followed by the spinous layer, granular layer, and stratum corneum. Most of the cells in each layer are keratinocytes differentiated from the basal layer. Keratinocytes that divide and proliferate in the basal layer differentiate into keratinocytes as they pass through the spinous layer and granular layer, forming the stratum corneum composed of keratin protein fibers with strong cross-linking, and finally falling off from the stratum corneum as scum. This stratum corneum is present in the outermost shell of the skin and serves as a physical barrier against stimuli from the outside world. To provide this barrier function, the skin repeats a cycle (keratinization) from when keratinocytes are produced in the basal layer until they become scum and fall off, usually in a four-week cycle, and the metabolism of the epidermis is carried out.
[0003] However, when the skin is exposed to external factors such as ultraviolet rays, extremely dry air, excessive skin washing, smoking, etc., or when the skin ages, the activity and proliferation ability of epidermal cells declines, and the turnover rate of the epidermis slows down, causing differentiation failure such as thinning of the epidermis and thickening of the stratum corneum. As a result, the moisturizing function and elasticity of the skin declines, abnormal peeling of the stratum corneum occurs, and the skin ages, causing changes such as wrinkles, dullness, loss of texture, and loss of elasticity.
[0004] Therefore, if the proliferation of keratinocytes can be promoted, skin turnover will be promoted and the metabolic function of the skin will be restored, which is believed to improve skin aging such as fine wrinkles, dullness, pigmentation, etc. Conventionally, extracts from Taiso (see Patent Document 1), extracts from Tsuchigai Mo (see Patent Document 2), etc. are known to have the effect of promoting the proliferation of epidermal keratinocytes.
[0005] The structure of the stratum corneum is likened to bricks and mortar, with 15 layers of keratinocytes stacked together by intercellular lipids, forming a strong barrier membrane. A strong structure called the cornified envelope (CE) is formed inside the cell membrane of keratinocytes, and moisture is maintained by the natural moisturizing factors, mainly composed of amino acids, contained within the cells. On the other hand, the intercellular lipids of keratinocytes are mainly composed of about 50% ceramide, and are composed of amphiphilic lipids such as cholesterol and fatty acids, and are characterized by a layered structure in which hydrophobic and hydrophilic parts are alternately repeated, a so-called lamellar structure.
[0006] The peripheral zone (CE) is formed when multiple CE component proteins produced in response to the differentiation of epidermal keratinocytes are cross-linked and insolubilized by the enzyme transglutaminase. Furthermore, ceramides and other molecules are covalently bonded to form a hydrophobic structure, providing a base for the lamellar structure of intercellular lipids in part of the CE, thereby forming the basis for the stratum corneum barrier function.
[0007] Involucrin is known as one of the CE component proteins expressed in the early stage of CE formation, and loricrin is known as one of the main component proteins of CE. It is believed that promoting the production of involucrin and loricrin improves the stratum corneum barrier function and prevents, treats, or improves skin aging symptoms such as rough skin and dry skin, and dry skin diseases such as atopic dermatitis, psoriasis, ichthyosis, and xerosis. Conventionally, 2-ketoglutaric acid and the like have been known to have an effect of promoting involucrin mRNA expression (see Patent Document 3), and cordyceps extracts and the like have been known to have an effect of promoting loricrin production (see Patent Document 4).
[0008] Filaggrin is a component of the skin, and is thought to be involved in the barrier function of the skin and to have the function of preventing the invasion of allergens, toxins, and infectious organisms. It is known that a decrease in function due to gene mutations of filaggrin is associated with the risk of developing atopic diseases including atopic dermatitis (eczema, skin inflammation, skin itchiness, etc.), allergies, asthma, etc., and in more severe cases, it can lead to skin diseases such as ichthyosis vulgaris (see Non-Patent Document 1).
[0009] On the other hand, amino acids, which are the main components of natural moisturizing factors (NMF), are produced by the decomposition of filaggrin derived from keratohyalin granules in the stratum corneum. This filaggrin is expressed as profilaggrin in epidermal keratinocytes present in the granular layer just below the stratum corneum. It is then immediately phosphorylated, accumulated in keratohyalin granules, decomposed into filaggrin through dephosphorylation and hydrolysis, and transferred to the stratum corneum, where it is known to increase the aggregation efficiency of keratin filaments and participate in the internal construction of keratinocytes (see Non-Patent Document 2). In recent years, it has been known that this filaggrin is very important and essential for moisture retention in the skin, and that the synthetic ability of filaggrin decreases under conditions such as dryness, and the amount of amino acids in the stratum corneum decreases (see Non-Patent Document 3).
[0010] Therefore, it is believed that by promoting the expression of filaggrin (profilaggrin) in epidermal keratinocytes, atopic diseases including atopic dermatitis (eczema, skin inflammation, skin itchiness, etc.), allergies, asthma, etc. can be prevented, treated, or improved. In addition, it is expected that by promoting the expression of filaggrin and thereby increasing the amount of amino acids in the stratum corneum, the moisture environment of the stratum corneum can be essentially improved. As a substance having a filaggrin expression promoting effect, Gaiyo extract (see Patent Document 5) and the like are known.
[0011] Caspase is an abbreviation of cysteine-aspartic-acid-protease and is a type of cysteine protease. To date, 14 types of caspases have been discovered, from caspase-1 to caspase-14. Of these, caspase-14 is known to have the ability to degrade filaggrin, a basic protein present in the epidermis, to produce natural moisturizing factor (NMF).
[0012] Therefore, it is believed that by promoting the expression of caspase-14, the production of natural moisturizing factors (NMFs) can be promoted, and the decline in the barrier function and moisture retention function of the skin can be prevented or improved. In addition, it is believed that by preventing or improving the decline in the barrier function of the skin through the promotion of the expression of caspase-14, it is possible to prevent, treat or improve skin diseases such as atopic dermatitis and ichthyosis, which are believed to be caused in part by the decline in the barrier function of the skin. Conventionally, yeast extracts (Patent Document 6) and the like are known to have the effect of promoting the expression of caspase-14.
[0013] In healthy skin, keratinocytes (epidermal keratinocytes) differentiate to continuously produce keratinocytes, and at the same time, old and unnecessary keratinocytes become dandruff and peel off, so that the stratum corneum is maintained at a constant thickness, and this process of skin turnover is repeated. However, it is known that the barrier function of the skin is reduced by external factors such as dryness, ultraviolet rays, and chemicals, and by internal factors such as oxidative stress and aging, and that these factors can cause abnormalities in skin turnover.
[0014] The stratum corneum is formed by adhesion between keratinocytes via an adhesive structure called corneodesmosome. Corneodesmosome is composed of multiple proteins including desmoglein 1 (DSG1) and desmocollin 1 (DSC1). Corneodesmosome is known to be cleaved by proteases such as kallikrein 5 (KLK5), a trypsin-like serine protease, and kallikrein 7 (KLK7), a chymotrypsin-like serine protease (see Non-Patent Documents 4 and 5).
[0015] In healthy skin, normal stratum corneum peeling occurs when corneodesmosomes are degraded by the serine protease. In normal stratum corneum peeling, the peeling is rarely recognized by the naked eye. However, when the activity of the serine protease is reduced due to skin troubles such as rough skin or aging, the decomposition of corneodesmosomes is delayed, causing the accumulation of keratinocytes, preventing smooth peeling, and the keratinocytes peel off in clumps, which are recognized as scales (see Non-Patent Document 6). Many skin diseases accompanied by abnormalities in the stratum corneum peeling function have been reported, such as senile xerosis, dandruff, ichthyosis vulgaris, sex-linked ichthyosis, and psoriasis (see Non-Patent Documents 7 to 9).
[0016] The serine protease activity in the epidermis is tightly regulated by serine protease inhibitors such as lymphoepithelial Kazal-type inhibitor (LEKTI) encoded by the serine peptidase inhibitor Kazal type 5 (SPINK5) gene. In patients with severe congenital ichthyosis-like erythroderma known as Netherton syndrome, the SPINK5 gene has been identified as the defective gene, and the activity of serine proteases such as KLK7 is increased, resulting in enhanced protein degradation.
[0017] Thus, promoting the production of KLK5 and KLK7 is important for promoting skin turnover. However, excessive production of KLK5 and KLK7 may cause abnormal desquamation. Therefore, in normal stratum corneum delamination, serine proteases such as KLK5 and KLK7 act on corneodesmosomes to degrade them, promoting stratum corneum delamination, and at the same time, serine protease inhibitors such as LEKTI regulate and balance the serine protease activity, thereby maintaining the homeostasis of protease activity in the skin.
[0018] Therefore, it is expected that by regulating the balance between the activity of serine proteases such as KLK5 and KLK7 in the skin and the activity of serine protease inhibitors such as LEKTI, it is possible to maintain the homeostasis of protease activity in the skin, improve the skin barrier function, and also improve skin turnover.
[0019] In addition, it was previously believed that only the stratum corneum was responsible for the barrier function of the skin, but since the barrier function of the skin collapses when the constituent proteins of tight junctions (hereinafter sometimes abbreviated as TJ) present in the granular layer of the epidermis are deleted at the genetic level, it is thought that TJ also plays an important role in the barrier function of the skin in recent years (see Non-Patent Document 10). TJ is a binding device that not only brings adjacent cells into close contact with each other, but also controls the permeation of substances by sealing the gaps between cells. Proteins that constitute this TJ include claudin, occludin, ZO-1, and ZO-2, and these proteins are thought to form the skeleton of the TJ strand and control the barrier function of TJ (see Non-Patent Document 11). From the above, if the expression of claudin, occludin, ZO-1, and ZO-2 is reduced for some reason, structural destruction of TJ occurs, and it is expected that it will no longer function as a barrier to permeation of substances, causing skin symptoms such as dry skin, rough skin, atopic dermatitis, and various infectious diseases.
[0020] Therefore, it is believed that by promoting the production of ZO-1 in the epidermis and thereby promoting TJ formation in epidermal keratinocytes, the barrier function and moisture retention function of the skin can be enhanced, and the above-mentioned skin symptoms can be prevented or improved. Based on this idea, natural products such as Coptis japonica extract (see Patent Document 7) and Picea abies extract (see Patent Document 8) have been disclosed as substances that improve skin barrier function through the action of promoting TJ formation.
[0021] Itching can occur for a variety of reasons, including dryness, irritation from foreign objects, and atopic dermatitis, and is known to involve chemical mediators such as histamine, and antihistamines and the like are used to suppress these chemical mediators. However, it is known that there is also itching that does not respond to antihistamines and the like (intractable itching), and it is believed that there is also an itching mechanism that does not involve histamine and the like.
[0022] In normal skin, nerve fibers (C fibers) that transmit itching and pain terminate at the dermal-epidermal junction, but in recent years, it has been found that in skin with atopic dermatitis and dry skin, the nerve fibers extend into the epidermis, especially to just below the stratum corneum. This state is thought to be deeply involved in the symptoms of so-called sensitive skin, in which nerve fibers are easily activated by external stimuli such as mechanical, chemical, and physical stimuli, and itching and pain are easily perceived.
[0023] It is known that the intraepidermal extension of nerve fibers involves the nerve growth factor (NGF), which is a nerve extension factor, and semaphorin 3A (Sema3A), which is a nerve repulsive factor. In normal skin, Sema3A is dominant over NGF, so nerve fibers cannot extend into the epidermis, but in atopic dermatitis and dry skin, NGF is dominant over Sema3A, which is thought to be why nerve fibers penetrate into the epidermis (see Non-Patent Document 12). It has also been reported that intradermal administration of Sema3A protein to dermatitis model mice improves skin rash and reduces pruritus (see Patent Document 9). Therefore, if the nerve repulsion action of Sema3A can be promoted, it is thought that pain and itching in atopic dermatitis, dry skin, sensitive skin, etc. can be suppressed.
[0024] Furthermore, it has recently been revealed that Sema3A exhibits the effect of increasing bone mass (bone protective effect) by simultaneously inhibiting osteoclast differentiation and promoting osteoblast differentiation, and Sema3A is expected to be used as a drug that combines the dual aspects of inhibiting bone resorption and promoting bone formation (Non-patent Document 13).
[0025] Conventionally, Scutellaria root extract and the like have been proposed as components that promote the expression of Sema3A (see Patent Document 10).
[0026] SIRT1 is a protein that belongs to a family called sirtuin, and is known to exist in the cell nucleus and cytoplasm and function as an NAD-dependent protein deacetylase. In recent years, it has been revealed that SIRT1 plays an important role in suppressing cellular aging, and is particularly expressed in skin tissue and is involved in the suppression of skin aging (see Non-Patent Document 14). In addition, it has been revealed that SIRT1 has various functions such as diabetes improvement, cardiovascular protection, renal disease improvement, inflammatory cytokine production suppression, and neuroprotection, in addition to cellular aging. Therefore, it is believed that if SIRT1 can be activated, it will be useful for preventing, treating, or improving various diseases such as aging such as skin aging, diabetes, cardiovascular disease, nervous system disease, and inflammatory disease. [Prior art documents] [Patent documents]
[0027] [Patent Document 1] JP 2006-316028 A [Patent Document 2] JP 2006-056854 A [Patent Document 3] Patent Publication No. 2021-127344 [Patent Document 4] Japanese Patent Publication No. 2014-040398 [Patent Document 5] Japanese Patent Publication No. 2012-219047 [Patent Document 6] JP-2022-144014 [Patent Document 7] Japanese Patent Publication No. 2007-176830 [Patent Document 8] Japanese Patent Publication No. 2007-176835 [Patent Document 9] Japanese Patent Publication No. 2008-297243 [Patent Document 10] Japanese Patent Publication No. 2016-193863
Non-licensed documents
[0028]
Non-patent document 1
Non-patent document 2
Non-patent document 3
Non-patent document 4
Non-patent document 5
Non-patent document 6
Non-patent document 7
Non-patent document 8
[0029] The present invention aims to find a component derived from a natural product that has a skin barrier function improving effect, and to provide a skin barrier function improving agent containing the component as an active ingredient. [Means for solving the problem]
[0030] In order to solve the above problems, the skin barrier function improving agent of the present invention is characterized in that it contains as active ingredients a combination of yeast fermented rice and one or more selected from the group consisting of chinese ginger extract, aloe vera extract, noni juice, coix seed extract, and satsuma mandarin extract. In addition, the filaggrin mRNA expression promoter, involucrin mRNA expression promoter, loricrin mRNA expression promoter, kallikrein 5 mRNA expression promoter, kallikrein 7 mRNA expression promoter, serine peptidase inhibitor Kazal type 5 (SPINK5) mRNA expression promoter, caspase 14 mRNA expression promoter, ZO-1 mRNA expression promoter, semaphorin 3A mRNA expression promoter, epidermal keratinocyte proliferation promoter, and sirtuin 1 mRNA expression promoter of the present invention are characterized by having a more specific combination of the above combinations as active ingredients. In the above invention, the yeast fermentation product of rice is preferably a Saccharomyces verona fermentation product. Effect of the Invention
[0031] According to the present invention, by using a combination of a yeast fermentation product of rice and a specific ingredient as the active ingredient, it is possible to provide a skin barrier function improver, a filaggrin mRNA expression promoter, an involucrin mRNA expression promoter, a loricrin mRNA expression promoter, a kallikrein 5 mRNA expression promoter, a kallikrein 7 mRNA expression promoter, a serine peptidase inhibitor Kazal type 5 (SPINK5) mRNA expression promoter, a caspase 14 mRNA expression promoter, a ZO-1 mRNA expression promoter, a semaphorin 3A mRNA expression promoter, an epidermal keratinocyte proliferation promoter, and a sirtuin 1 mRNA expression promoter with excellent effects. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0032] Hereinafter, an embodiment of the present invention will be described. The skin barrier function improving agent of this embodiment contains as active ingredients a combination of yeast fermented rice and one or more selected from the group consisting of chinese ginger extract, aloe vera extract, noni juice, coix seed extract, and satsuma mandarin extract.
[0033] [Rice fermented with yeast] In this embodiment, a fermented product obtained by fermenting rice with yeast (hereinafter referred to as "yeast fermented rice product") is used as one of the active ingredients.
[0034] In the yeast-fermented rice product according to the present embodiment, the rice used as the fermentation raw material is the fruit of the grass plant rice (scientific name: Oryza sativa). Rice is cultivated throughout Japan and is easily available from these regions. There are no particular limitations on the fermentation raw material, and it can be appropriately selected depending on the purpose. Examples of the fermentation raw material include unhulled rice, brown rice, polished rice, and mixtures thereof, and polished rice is preferred among these.
[0035] The yeast fermented rice product according to the present embodiment can be obtained by fermenting rice with yeast. The fermentation treatment can be carried out, for example, by dispersing rice in water and inoculating the rice with yeast that performs fermentation.
[0036] From the viewpoint of increasing fermentation efficiency, it is preferable to carry out a treatment to decompose starch contained in rice and / or a treatment to decompose rice cell walls prior to inoculation with the yeast.
[0037] Examples of starch decomposition treatment include enzyme treatment and inoculation with koji mold, and enzyme treatment is particularly preferred. Examples of starch decomposition enzymes include amylases such as α-amylase, β-amylase, glucoamylase, and isoamylase, and from the viewpoint of increasing fermentation efficiency, α-amylase and glucoamylase are particularly preferred, and glucoamylase is even more preferred. On the other hand, cell wall decomposition treatment is preferably performed using enzymes such as cellulase and xylanase.
[0038] The resulting treated liquid may be subjected to a desired means such as cooling, heating, pH adjustment, or sterilization to inactivate the enzymes and koji mold, or it may be inoculated with yeast for fermentation as is.
[0039] Examples of yeasts that perform fermentation include Saccharomyces cerevisiae (baker's yeast), Saccharomyces veronae, Schizosaccharomyces pombe, Kluyveromyces thermotolerans, Zygosaccharomyces thermotolerans, Lachancea thermotolerans, Candida utilis, and others. Preferred examples include the genus Candida, such as Candida utilis and Torula yeast. In this embodiment, these yeasts can be used alone or in combination of two or more. When using two or more types in combination, fermentation may be carried out simultaneously with two or more types of yeast, or primary fermentation with koji mold may be carried out first, followed by secondary fermentation with yeast.
[0040] Among these, the yeast used in this embodiment is particularly preferably yeast of the genus Saccharomyces or Lachancea, from the viewpoint of safety when used in skin cosmetics or foods and beverages, and from the viewpoint of the action of the fermented rice product, and more preferably Saccharomyces veronae (also known as Lachancea thermotolerans). Here, Saccharomyces veronae (also known as Lachancea thermotolerans) is different from other yeasts such as Saccharomyces cerevisiae in that it does not substantially perform alcoholic fermentation.
[0041] The fermentation treatment using the yeast can be carried out, for example, by placing the fermentation raw material and the yeast in a fermenter and treating for 12 to 72 hours, preferably 18 to 48 hours, at a temperature range of 20 to 40°C, preferably 25 to 35°C. The fermentation treatment proceeds smoothly if the pH of the reaction liquid is adjusted to 5.0 to 7.0, preferably 6.0 to 7.0, at the start of the fermentation treatment. The fermentation treatment is terminated by subjecting the fermentation liquid to a desired means such as cooling, heat sterilization, or filtration to inactivate the fermenting bacteria.
[0042] The fermentation liquid thus obtained may be used as the fermented product as it is, or may be appropriately diluted or concentrated before use as the fermented product. Furthermore, the concentrate may be further dried or subjected to crude purification. In this specification, unless otherwise specified, the term "yeast fermented rice product" includes a fermentation liquid obtained by fermenting rice with yeast, a diluted liquid or concentrated liquid of the fermentation liquid, a dried product obtained by drying the fermentation liquid, or a crude or purified product thereof. Hereinafter, the yeast fermented rice product may be simply referred to as "rice fermented product".
[0043] The yeast fermented rice product obtained in the manner described above can exhibit excellent effects such as improving skin barrier function, and can be used alone as an active ingredient of a skin barrier function improving agent, etc. However, when used in combination with the below-mentioned chinese ginger extract, aloe vera extract, noni juice, coix seed extract, and satsuma mandarin extract, it exhibits particularly excellent effects such as improving skin barrier function.
[0044] [Ginger extract, aloe vera extract, coix seed extract, satsuma mandarin extract] In this embodiment, the extraction raw materials used to produce the Gaiyo extract, Aloe vera extract, Coix seed extract, and Satsuma mandarin extract are Gaiyo (herbal medicine name), Aloe vera (scientific name: Aloe vera), Coix seed (herbal medicine name) and Satsuma mandarin (scientific name: Citrus unshiu Marcow), respectively.
[0045] Gaiyo (herbal medicine name) is the leaf of mugwort (scientific name: Artemisia princeps Pampanini), a perennial herb belonging to the Asteraceae family that is distributed throughout Japan and can be easily obtained from these areas. Gaiyo has traditionally been used to stop bleeding in the gynecological field, prevent miscarriage, and prevent abdominal pain due to cold symptoms.
[0046] Aloe vera is a succulent plant belonging to the genus Aloe in the family Liliaceae, which is cultivated in Africa, India, etc. and can be easily obtained from these regions. The constituent parts of Aloe vera that can be used as the extraction raw material can be appropriately selected depending on the purpose, and examples thereof include leaves, mesophyll, stems, flowers, fruits, peels, stalks, seeds, roots, mixtures of these, or the whole plant, or juice (squeezed liquid) obtained by squeezing these, concentrates thereof, dried products thereof, etc., and it is preferable to use a concentrate or dried product of the squeezed liquid of the mesophyll.
[0047] Job's tears (coix lachrymal-jobi L.) is the seed of Job's tears. Job's tears is a plant native to China and Indochina, and is an annual plant belonging to the genus Job's tears of the family Poaceae that is cultivated in the warm southwestern part of Japan, and can be easily obtained from these regions. Job's tears has traditionally been used for purposes such as irrigation, draining dampness, clearing heat, draining pus, removing paralysis, strengthening the spleen, and relieving pain.
[0048] Citrus unshiu (Citrus unshiu Marcow) is a plant of the Rutaceae family, and is mainly cultivated in coastal areas south of the Kanto region, and can be easily obtained from these areas. The parts of Citrus unshiu that can be used as the extraction raw material can be appropriately selected depending on the purpose, and examples thereof include leaves, stems, branches, flowers, buds, fruits, peels, pits, seeds, roots, and mixtures thereof, and the peels are preferred.
[0049] The extract from the above-mentioned plant can be obtained by drying the extraction raw material, pulverizing it using a crusher, and then subjecting it to extraction using an extraction solvent. Drying can be performed in the sun or using a commonly used dryer. In addition, the raw material may be used after pretreatment such as degreasing with a non-polar solvent such as hexane. By performing pretreatment such as degreasing, extraction treatment using a polar solvent can be performed efficiently.
[0050] As the extraction solvent, it is preferable to use a polar solvent, such as water or a hydrophilic organic solvent, which is preferably used alone or in combination of two or more at room temperature or at a temperature below the boiling point of the solvent.
[0051] Water that can be used as an extraction solvent includes pure water, tap water, well water, mineral water, hot spring water, spring water, fresh water, etc., as well as water that has been subjected to various treatments. Treatments that can be applied to water include, for example, purification, heating, sterilization, filtration, ion exchange, osmotic pressure adjustment, buffering, etc. Therefore, water that can be used as an extraction solvent in this embodiment also includes purified water, hot water, ion-exchanged water, physiological saline, phosphate buffer, phosphate buffered physiological saline, etc.
[0052] Examples of hydrophilic organic solvents that can be used as the extraction solvent include lower aliphatic alcohols having 1 to 5 carbon atoms, such as methanol, ethanol, propyl alcohol, and isopropyl alcohol; polyhydric alcohols having 2 to 5 carbon atoms, such as 1,3-butylene glycol, propylene glycol, and glycerin; and lower aliphatic ketones having 3 to 4 carbon atoms, such as acetone and methyl ethyl ketone.
[0053] When a mixture of two or more polar solvents is used as an extraction solvent, the mixture ratio is arbitrary and can be adjusted appropriately. For example, when a mixture of water and a hydrophilic organic solvent is used as an extraction solvent, the mixture ratio can be arbitrarily mixed and used, that is, between more than 0:100 and less than 100:0 (volume ratio, hereinafter the same), and can be adjusted appropriately. For example, when a mixture of water and a lower aliphatic alcohol is used as an extraction solvent, the ratio (volume %) of the lower aliphatic alcohol in the mixture can be 10% or more, or even 30% or more, or the ratio (volume %) of the lower aliphatic alcohol in the mixture can be 90% or less, or even 80% or less. When a mixture of water and a polyhydric alcohol is used, the ratio (volume %) of the polyhydric alcohol in the mixture can be 20% or more, or 90% or less, and when a mixture of water and a lower aliphatic ketone is used, the ratio (volume %) of the lower aliphatic ketone in the mixture can be 10% or more, or 80% or less.
[0054] The extraction process is not particularly limited as long as the soluble components contained in the extraction raw material can be dissolved in the extraction solvent, and can be performed according to a conventional method. For example, the extraction raw material is immersed in an extraction solvent in an amount 5 to 15 times (mass ratio) of the extraction raw material, and the soluble components are extracted at room temperature or under reflux heating, and then the extraction residue is removed by filtration to obtain an extract. The solvent is distilled off from the obtained extract to obtain a paste-like concentrate, and the concentrate is further dried to obtain a dry product. In addition, the "extract" in this embodiment includes an extract obtained using the above-mentioned plant as an extraction raw material, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, or any of these crude or purified products.
[0055] The thus obtained ginger extract, aloe vera extract, coix seed extract and satsuma mandarin extract can exert excellent effects such as improving the skin barrier function, and can be used alone as an active ingredient of a skin barrier function improving agent, but when used in combination with the aforementioned rice yeast fermentation product, they exert particularly excellent effects such as improving the skin barrier function.
[0056] [Noni juice] In this embodiment, the raw material for obtaining noni juice is noni (scientific name: Morinda citrifolia).
[0057] Noni (Morinda citrifolia), known as Yaeyama Aoki in Japan, is a plant of the Rubiaceae family, and is distributed in areas such as Okinawa to the Ogasawara Islands, Taiwan to China, and the coastal areas of India, and is easily available from these areas. The part used in this embodiment is the fruit. Noni juice can be obtained by squeezing the juice from the noni fruit using a juicer or similar device.
[0058] The obtained noni juice may be used as it is, or may be concentrated or dried to be used as a concentrate or a dried product. When dried, a freeze-dried product is preferred. In addition, the obtained noni fruit juice may be further subjected to an extraction process and used as an extract. The extraction solvent and extraction process described above for the plant extract can be suitably applied to the extraction of noni fruit juice.
[0059] The noni juice obtained in the manner described above can exert an excellent effect of improving the skin barrier function, and can be used alone as an active ingredient of a skin barrier function improving agent, etc. However, when used in combination with the aforementioned rice yeast fermentation product, it exerts an especially excellent effect of improving the skin barrier function, etc.
[0060] [Skin barrier function improver, FLG mRNA expression promoter, etc.] The yeast fermented rice product obtained as described above can exhibit excellent skin barrier function improving effects, etc., and can be used alone as an active ingredient of a skin barrier function improving agent, etc. In addition, the chinese ginger extract, aloe vera extract, noni fruit juice, coix seed extract, and satsuma mandarin extract (hereinafter, these may be abbreviated as "five ingredients") each exhibit excellent skin barrier function improving effects, etc., and can be used alone as an active ingredient of a skin barrier function improving agent, etc. However, in this embodiment, by using the yeast fermented rice in combination with the above five components, the skin barrier function improving effect can be dramatically improved.
[0061] The skin barrier function improving effect of the combination of the yeast fermented rice and the above five ingredients is exerted based on one or more actions selected from the group consisting of filaggrin (FLG) mRNA expression promoting action, involucrin (IVL) mRNA expression promoting action, loricrin (LOR) mRNA expression promoting action, kallikrein 5 (KLK5) mRNA expression promoting action, kallikrein 7 (KLK7) mRNA expression promoting action, serine peptidase inhibitor Kazal type 5 (SPINK5) mRNA expression promoting action, caspase 14 mRNA expression promoting action, ZO-1 mRNA expression promoting action, semaphorin 3A (Sema3A) mRNA expression promoting action, and epidermal keratinocyte proliferation promoting action. However, the skin barrier function improving action of the combination of the yeast fermented rice and the above five ingredients is not limited to the skin barrier function improving action exerted based on the above actions.
[0062] In addition, specific combinations of the yeast fermented rice and the above five ingredients may be used as active ingredients of an FLG mRNA expression promoter, an IVL mRNA expression promoter, an LOR mRNA expression promoter, a KLK5 mRNA expression promoter, a KLK7 mRNA expression promoter, a SPINK5 mRNA expression promoter, a caspase 14 mRNA expression promoter, a ZO-1 mRNA expression promoter, a Sema3A mRNA expression promoter, or an epidermal keratinocyte proliferation promoter, through the action of each combination.
[0063] The above specific combination will now be described in detail. A combination of yeast fermented rice and a Gaiyo extract can be used as an active ingredient of an FLG mRNA expression promoter. A combination of yeast fermented rice and a Gaiyo extract and / or a Coix seed extract can be used as an active ingredient of an IVL mRNA expression promoter. A combination of yeast fermented rice and one or more selected from the group consisting of chinese ginger extract, aloe vera extract, noni juice, and coix seed extract can be used as an active ingredient of an LOR mRNA expression promoter.
[0064] A combination of yeast fermented rice and Gaiyo extract can be used as an active ingredient of a KLK5 mRNA expression promoter. A combination of yeast fermented rice and Gaiyo extract and / or Noni juice can be used as an active ingredient of a KLK7 mRNA expression promoter. A combination of yeast fermented rice and one or more selected from the group consisting of cockle extract, noni juice, coix seed extract, and satsuma mandarin extract can be used as an active ingredient of a SPINK5 mRNA expression promoter.
[0065] A combination of yeast fermented rice and Gaiyo extract and / or Noni juice can be used as an active ingredient of an agent for promoting caspase 14 mRNA expression. A combination of yeast fermented rice and one or more selected from the group consisting of chinese ginger extract, aloe vera extract, coix seed extract, and satsuma mandarin extract can be used as an active ingredient of a ZO-1 mRNA expression promoter.
[0066] A combination of yeast fermented rice and one or more selected from the group consisting of cockle extract, aloe vera extract, noni juice, and Satsuma mandarin extract can be used as an active ingredient of a Sema3A mRNA expression promoter. A combination of yeast fermented rice and one or more selected from the group consisting of chinese ginger extract, aloe vera extract, noni juice, and satsuma mandarin extract can be used as an active ingredient of an epidermal keratinocyte proliferation promoter.
[0067] Furthermore, the combination of yeast fermented rice and extract of Gaiyo has the effect of promoting the expression of Sirtuin 1 (SIRT1) mRNA, and therefore can be used as an active ingredient of an agent for promoting the expression of SIRT1 mRNA. Hereinafter, these agents (agents other than skin barrier function improving agents) may be collectively referred to as "FLG mRNA expression promoters, etc.", and their actions and uses may also be collectively referred to as "FLG mRNA expression promoting effect, etc." and "Uses of FLG mRNA expression promoting, etc."
[0068] According to this embodiment, a combination of rice yeast fermentation product and the above five components can be used to produce a skin barrier function improvement agent, and the above specific combination can be used to produce an FLG mRNA expression promoter, etc. The skin barrier function improving agent and FLG mRNA expression promoter of this embodiment can be used in a wide range of applications, such as medicines, quasi-drugs, cosmetics, and oral compositions.
[0069] One of each of the five components, namely, chinese ginger extract, aloe vera extract, noni juice, coix seed extract, and satsuma mandarin extract, may be combined with the rice fermentation product by yeast, or two or more of the five components may be combined with the rice fermentation product by yeast.
[0070] In the skin barrier function improving agent and FLG mRNA expression promoter of this embodiment, the blending ratio of the yeast fermented rice product and the above five components can be appropriately set according to their activities, and for example, the total of the above five components can be 2 parts by mass or more, 5 parts by mass or more, 10 parts by mass or more, or 20 parts by mass or more per 100 parts by mass of the yeast fermented rice product (solid content equivalent, the same applies below). Also, the total of the above five components can be 1000 parts by mass or less, 500 parts by mass or less, 150 parts by mass or less, or 100 parts by mass or less per 100 parts by mass of the yeast fermented rice product.
[0071] The skin barrier function improving agent and FLG mRNA expression promoting agent of this embodiment may consist solely of a combination of rice yeast fermentation product and the above five ingredients, or may be a formulation of the combination of rice yeast fermentation product and the above five ingredients.
[0072] The skin barrier function improving agent and FLG mRNA expression promoting agent of the present embodiment can be formulated into any dosage form such as powder, granules, tablets, liquid, etc., using pharma- ceutically acceptable carriers such as dextrin, cyclodextrin, and other optional auxiliary agents according to a conventional method. In this case, examples of auxiliary agents that can be used include excipients, binders, disintegrants, lubricants, stabilizers, flavorings, and odorants. The skin barrier function improving agent and FLG mRNA expression promoting agent can be used by blending them with other compositions (e.g., skin cosmetics, oral compositions, etc.), and can also be used as ointments, external liquids, patches, etc.
[0073] When the skin barrier function improvement agent and FLG mRNA expression promoter of this embodiment are formulated, the content of the combination of the yeast fermented rice product and the above five components is not particularly limited and can be set appropriately depending on the purpose.
[0074] In addition, the skin barrier function improving agent and FLG mRNA expression promoting agent of this embodiment can be used as active ingredients by blending other natural extracts having skin barrier function improving effects or FLG mRNA expression promoting effects, etc., together with the combination of rice yeast fermentation product and the above five components, if necessary.
[0075] Methods for administering the skin barrier function improving agent and FLG mRNA expression promoter of this embodiment to a patient include transdermal administration, oral administration, etc., and a method suitable for prevention, treatment, etc. may be appropriately selected depending on the type of disease. Furthermore, the dosage of the skin barrier function improving agent and FLG mRNA expression promoter of this embodiment may be appropriately increased or decreased depending on the type and severity of the disease, individual differences in patients, administration method, administration period, etc.
[0076] The skin barrier function improving agent of this embodiment can improve the barrier function of the skin and can improve the moisture retention function of the skin through one or more actions selected from the group consisting of FLG mRNA expression promoting action, IVL mRNA expression promoting action, LOR mRNA expression promoting action, KLK5 mRNA expression promoting action, KLK7 mRNA expression promoting action, SPINK5 mRNA expression promoting action, caspase 14 mRNA expression promoting action, ZO-1 mRNA expression promoting action, Sema3A mRNA expression promoting action, and epidermal keratinocyte proliferation promoting action, which are possessed by the combination of the yeast fermented rice product as an active ingredient and the above five ingredients. The improvement of the barrier function and moisture retention function of the skin is effective in preventing, treating, or improving not only rough skin and dry skin, but also dry skin diseases (e.g., atopic dermatitis, psoriasis, ichthyosis, dandruff, etc.), and various infectious diseases transmitted through the skin.
[0077] The skin barrier function improving agent, KLK5 mRNA expression promoter, KLK7 mRNA expression promoter, SPINK5 mRNA expression promoter, epidermal keratinocyte proliferation promoter, and SIRT1 mRNA expression promoter of this embodiment can improve epidermal turnover through their KLK5 mRNA expression promoting effect, KLK7 mRNA expression promoting effect, SPINK5 mRNA expression promoting effect, epidermal keratinocyte proliferation promoting effect, or SIRT1 mRNA expression promoting effect. In addition, the skin barrier function improving agent, KLK5 mRNA expression promoter, KLK7 mRNA expression promoter, and SPINK5 mRNA expression promoter of this embodiment can normalize stratum corneum desquamation through their KLK5 mRNA expression promoting effect, KLK7 mRNA expression promoting effect, or SPINK5 mRNA expression promoting effect. The skin barrier function improving agent or ZO-1 mRNA expression promoting agent of this embodiment can promote the formation of tight junctions through its ZO-1 mRNA expression promoting effect.
[0078] The Sema3A mRNA expression promoter of this embodiment promotes the expression of Sema3A mRNA in the skin (particularly in the epidermis) through its Sema3A mRNA expression promoting action, thereby suppressing the intraepidermal extension of nerve fibers. Inhibition of intraepidermal extension of nerve fibers is effective in suppressing skin itching and pain (particularly itching and pain that are not dependent on chemical mediators such as histamine), for example, itching and pain in atopic dermatitis, dry skin, sensitive skin, etc. Furthermore, the Sema3A mRNA expression promoter of this embodiment suppresses osteoclast differentiation and promotes osteoblast differentiation through its Sema3A mRNA expression promoting action, and can be used for increasing bone mass (bone protection). The epidermal keratinocyte proliferation promoter of the present embodiment, through its epidermal keratinocyte proliferation promoting action, improves the barrier function and moisture retention function of the skin, improves epidermal turnover, and also restores the metabolic function of the skin, such as shedding of keratinocytes with abnormal accumulation of melanin from the stratum corneum, thereby preventing and improving symptoms such as dullness and pigmentation of the skin. It can also be used in applications such as regenerative medicine, which require the promotion of epidermal keratinocyte proliferation. The SIRT1 mRNA expression promoter of this embodiment, by virtue of its SIRT1 mRNA expression promoting effect, can be used for the prevention, treatment, or amelioration of various diseases such as metabolic diseases, inflammatory diseases, cellular aging, diabetes, cardiovascular diseases, renal diseases, and neurological diseases, as well as for various phenomena involving Sirtuin 1, such as anti-aging and prolongation of lifespan.
[0079] However, in addition to the uses mentioned above, the skin barrier function improving agent, FLG mRNA expression promoter, IVL mRNA expression promoter, LOR mRNA expression promoter, KLK5 mRNA expression promoter, KLK7 mRNA expression promoter, SPINK5 mRNA expression promoter, caspase 14 mRNA expression promoter, ZO-1 mRNA expression promoter, Sema3A mRNA expression promoter, epidermal keratinocyte proliferation promoter, and SIRT1 mRNA expression promoter of this embodiment can be used for all uses in which it is meaningful to exert a skin barrier function improving effect, an FLG mRNA expression promoting effect, an IVL mRNA expression promoting effect, an LOR mRNA expression promoting effect, an KLK5 mRNA expression promoting effect, an KLK7 mRNA expression promoting effect, an SPINK5 mRNA expression promoting effect, a caspase 14 mRNA expression promoting effect, an ZO-1 mRNA expression promoting effect, an Sema3A mRNA expression promoting effect, an epidermal keratinocyte proliferation promoting effect, and a SIRT1 mRNA expression promoting effect, respectively.
[0080] In addition, the skin barrier function improving agent and FLG mRNA expression promoting agent of the present embodiment have excellent skin barrier function improving action and FLG mRNA expression promoting action, etc., respectively, and are therefore suitable for, for example, blending into skin external preparations. In this case, the combination of the rice yeast fermentation product and the above-mentioned five components may be blended as is, or the combination of the rice yeast fermentation product and the above-mentioned five components may be formulated and then blended. Here, the skin external preparation is not limited to its classification, and includes a wide range of transdermal quasi-drugs, pharmaceuticals, etc., in addition to skin cosmetics described below.
[0081] [Incorporation into skin cosmetics] The combination of the rice yeast fermentation product and the above five ingredients is suitable for incorporation into skin cosmetics because it has excellent effects of improving skin barrier function and promoting FLG mRNA expression, etc. In this case, the combination of the rice yeast fermentation product and the above five ingredients may be incorporated as is, or the combination of the rice yeast fermentation product and the above five ingredients may be formulated and then incorporated.
[0082] By blending the combination of the rice yeast fermentation product and the above five components, it is possible to obtain a skin cosmetic suitable for improving skin barrier function. In addition, by blending the above specific combination, it is possible to obtain a skin cosmetic suitable for promoting FLG mRNA expression, promoting IVL mRNA expression, promoting LOR mRNA expression, promoting KLK5 mRNA expression, promoting KLK7 mRNA expression, promoting SPINK5 mRNA expression, promoting caspase 14 mRNA expression, promoting ZO-1 mRNA expression, promoting Sema3A mRNA expression, promoting epidermal keratinocyte proliferation, or promoting SIRT1 mRNA expression. In other words, blending into a skin external preparation is one of the suitable uses of a skin barrier function improving agent or an FLG mRNA expression promoter.
[0083] There are no particular limitations on the type of skin cosmetic that can contain the combination of the yeast fermented rice and the above five components, and examples of skin cosmetic products include ointments, creams, milky lotions, skin toners, lotions, gels, beauty oils, packs, foundations, shampoos, and rinses.
[0084] When the combination of the rice yeast fermentation product and the above five components is blended into a skin cosmetic, the blending amount can be adjusted as appropriate depending on the type of skin cosmetic, but a suitable blending ratio is approximately 0.0005 to 0.3 mass % calculated as the solid content of the combination of the rice yeast fermentation product and the above five components, and a particularly suitable blending ratio is approximately 0.001 to 0.3 mass %.
[0085] The skin cosmetic of this embodiment can be used in combination with main ingredients, auxiliaries, or other ingredients used in the manufacture of ordinary skin cosmetic products, such as astringents, germicides / antibacterial agents, whitening agents, UV absorbers, moisturizers, cell activators, anti-inflammatory / antiallergic agents, antioxidants / active oxygen removers, oils and fats, waxes, hydrocarbons, fatty acids, alcohols, esters, surfactants, fragrances, etc., so long as the combination of the rice fermentation product with the above five ingredients does not interfere with the skin barrier function improving effect and FLG mRNA expression promoting effect, etc. Using these ingredients in combination in this way can result in a more general product, and the synergistic effect with the other active ingredients used in combination can bring about an effect superior to that normally expected.
[0086] Incorporation into oral compositions The combination of the rice yeast fermentation product and the above five components has an excellent effect of improving the skin barrier function, and is therefore suitable for incorporation into an oral composition. In this case, the combination of the rice yeast fermentation product and the above five components may be incorporated as is, or may be formulated and then incorporated.
[0087] By blending the rice yeast fermentation product with the above five components, an oral composition suitable for improving skin barrier function can be obtained. In addition, by blending the above specific combination, an oral composition suitable for promoting FLG mRNA expression, promoting IVL mRNA expression, promoting LOR mRNA expression, promoting KLK5 mRNA expression, promoting KLK7 mRNA expression, promoting SPINK5 mRNA expression, promoting caspase 14 mRNA expression, promoting ZO-1 mRNA expression, promoting Sema3A mRNA expression, promoting epidermal keratinocyte proliferation, or promoting SIRT1 mRNA expression can be obtained. In other words, blending into an oral composition is one of the suitable uses for skin barrier function improving agents and FLG mRNA expression promoters.
[0088] Here, the oral composition refers to a composition that is unlikely to cause harm to human health and is taken orally or by administration to the digestive tract in normal social life, and is not limited to administrative classifications such as food, medicine, and quasi-drug. Therefore, the "oral composition" in this embodiment broadly includes general foods, health foods, health functional foods (foods for specified health uses, foods with nutritional functions, and foods with functional claims), quasi-drugs, medicines, and the like that are taken orally. The oral composition according to this embodiment is preferably an oral composition that can display the favorable effects of the combination of the yeast fermented rice and the above five components on the oral composition or its packaging, and is particularly preferably a health functional food (foods for specified health uses, foods with functional claims, and foods with nutritional functions), quasi-drugs, and medicines.
[0089] When the combination of the rice yeast fermentation product and the above five components is added to an oral composition, the amount of active ingredient in the combination can be appropriately changed considering the purpose of use, symptoms, sex, etc., but considering the general intake of the oral composition to be added, it is preferable to make the daily intake of the extract of the combination of the rice yeast fermentation product and the above five components equivalent to the solid content of the combination of the rice yeast fermentation product and the above five components about 1 to 1000 mg per adult. When the oral composition to be added is a granular, tablet, or capsule-shaped oral composition, the amount of the combination of the rice yeast fermentation product and the above five components added is usually 0.1 to 100% by mass, preferably 5 to 100% by mass, calculated as the solid content of the combination of the rice yeast fermentation product and the above five components, relative to the oral composition to be added.
[0090] The oral composition of this embodiment may be a combination of the yeast fermentation product of rice and the above five ingredients formulated into any oral composition that does not interfere with their activity, or it may be a nutritional supplement whose main ingredient is a combination of the yeast fermentation product of rice and the above five ingredients.
[0091] When producing the oral composition of this embodiment, any auxiliary agent can be added, for example, sugars such as dextrin, starch, etc.; proteins such as gelatin, soy protein, corn protein, etc.; amino acids such as alanine, glutamine, isoleucine, etc.; polysaccharides such as cellulose, gum arabic, etc.; fats and oils such as soybean oil, medium-chain fatty acid triglyceride, etc., to form an oral composition in any shape.
[0092] Oral compositions which may contain a combination of the yeast fermented rice product and the above five components are not particularly limited, and specific examples include beverages such as soft drinks, carbonated drinks, nutritional drinks, fruit drinks, and lactic acid drinks (including concentrated concentrates and powders for adjusting these beverages); frozen desserts such as ice cream, ice sherbet, and shaved ice; noodles such as soba, udon, vermicelli, gyoza wrappers, shumai wrappers, Chinese noodles, and instant noodles; sweets such as candy, chewing gum, candies, gum, chocolate, tablet candies, snacks, biscuits, jellies, jams, creams, and baked goods; processed seafood and livestock foods such as kamaboko, ham, and sausages; dairy products such as processed milk and fermented milk; oils and fats and oil-based processed foods such as salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, and dressings; seasonings such as sauces and sauces; soups, stews, salads, side dishes, and pickles; health and nutritional supplements in various forms; tablets, capsules, and energy drinks. When the combination of the yeast fermented rice and the above five ingredients is formulated into these oral compositions, commonly used auxiliary raw materials and additives can be used in combination.
[0093] Other embodiments The skin barrier function improving agent and FLG mRNA expression promoting agent of this embodiment each have excellent skin barrier function improving effects and FLG mRNA expression promoting effects, and therefore can also be suitably used as reagents for research into the mechanisms of these actions.
[0094] Furthermore, although the skin barrier function improving agent and FLG mRNA expression promoting agent of this embodiment are suitable for use in humans, they can also be applied to animals other than humans (e.g., mice, rats, hamsters, dogs, cats, cows, pigs, monkeys, etc.) as long as their respective functional effects are achieved. EXAMPLES
[0095] The present invention will be specifically explained below by showing Production Examples, Test Examples and Blending Examples, but the present invention is not limited to the following examples in any way.
[0096] [Production Example 1] Production of fermented rice
[0097] 0.1 kg of polished rice flour was dispersed in 1 kg of water and sterilized at 110°C for 5 minutes. After that, glucoamylase was added and the mixture was allowed to react at 60°C for 1 hour.
[0098] The resulting enzyme-treated liquid was then inoculated with Saccharomyces verona (Akita Konno Shoten) and fermented at 30°C for 24 hours. The resulting fermented liquid was sterilized at 110°C for 5 minutes. The resulting culture liquid was filtered through diatomaceous earth, and the filtrate was concentrated and dried to obtain a rice fermented product (approximately 64 g).
[0099] [Production Example 2] Production of Gaiyo extract 1500 mL of 80% ethanol solution was added to 100 g of dried mugwort leaves, and extraction was carried out for 2 hours at 80 to 90°C using a reflux extractor, followed by hot filtration. The resulting extract was dried to obtain Gaiyo extract (7.5 g).
[0100] [Production Example 3] Production of Unshu mandarin extract 100 g of dried Unshu mandarin peel was mixed with 80% ethanol by volume, and extracted for 2 hours at 80-90°C using a reflux extractor, followed by hot filtration. The resulting extract was dried to obtain Unshu mandarin extract (25 g).
[0101] [Production Example 4] Production of Aloe vera extract 100 mL of 30% by volume 1,3-butylene glycol solution was added to 1 g of solid obtained by concentrating the squeezed juice of the mesophyll of Aloe vera, and extraction was performed by heating at 50°C for 1 hour and then filtering. The obtained extract was dried to obtain an Aloe vera extract (0.8 g).
[0102] [Production Example 5] Production of Noni juice 1,3-butylene glycol and purified water were added to 100 g of noni juice, and the resulting liquid was dried to obtain a solid content (5 g) of noni juice.
[0103] [Production Example 6] Production of Job's tears extract 1500 mL of 50% by volume 1,3-butylene glycol solution was added to 100 g of crushed Job's tears seeds, extracted with heating, and filtered. The resulting extract was dried to obtain Job's tears extract (6 g).
[0104] [Test Example 1] Filaggrin (FLG) mRNA expression promoting effect test The fermented rice product (Production Example 1) and the Gaiyo extract (Production Example 2) were tested for their FLG mRNA expression promoting effect as follows.
[0105] Normal human neonatal epidermal keratinocytes (NHEK) were precultured in normal human epidermal keratinocyte growth medium (KGM) and the cells were harvested by trypsinization. The harvested cells were collected at a concentration of 1.5 × 10 5 After diluting with KGM to a cell density of 3.0 × 10 cells / mL, 2 mL of the cells were seeded into a 6-well plate (3.0 × 10 5 The cells were cultured overnight at 37℃ in 5% CO2 at 100μg / well. After culture, the medium was replaced with normal human epidermal keratinocyte basal medium (KBM, the above KGM without the addition of growth additives) and cultured for an additional 24 hours.
[0106] After 24 hours of incubation, the medium was removed and 2 mL of the test sample dissolved in KBM (see Table 1 below for sample concentration (converted to solid content)) was added to each well and incubated for 24 hours at 37°C and 5% CO2. As a control, KBM without added sample was used for incubation in the same manner. After incubation, the medium was removed and total RNA was extracted using ISOGEN II (Nippon Gene, Cat. No. 311-07361). The amount of each RNA was measured using a spectrophotometer (measurement wavelength: 260 nm) and total RNA was adjusted to 200 ng / μL.
[0107] Using this total RNA as a template, the expression levels of FLG and GAPDH as an internal standard were measured using a real-time PCR device, Thermal Cycler Dice. (R) Using Real Time System III (Takara Bio), PrimeScript TM RT Master Mix (Perfect Real Time) and TB Green (R) The assay was carried out by a two-step real-time RT-PCR reaction using Fast qPCR Mix (both manufactured by Takara Bio). Perfect Real Time Primer (manufactured by Takara Bio) was used as the primer. The expression level of FLG mRNA was calculated based on the total RNA samples prepared from cells cultured with and without the addition of the test sample, and the corrected value was calculated using the GAPDH value. The FLG mRNA expression promotion rate (%) was calculated from the obtained values using the following formula.
[0108] FLG mRNA expression promotion rate (%) = A / B × 100 Each term in the formula represents the following: A: Correction value when test sample is added B: Correction value without sample The results are shown in Table 1.
[0109] [Table 1]
[0110] As shown in Table 1, it was confirmed that the combined use of fermented rice and Gaiyo extract significantly improved the FLG mRNA expression promoting effect.
[0111] [Test Example 2] Involucrin (IVL) mRNA expression promoting effect test
[0112] The IVL mRNA expression promoting effect was tested in the same manner as in Test Example 1, except that the test samples were changed to rice fermentation product (Production Example 1), cockle extract (Production Example 2) and coix seed extract (Production Example 6) (see Tables 2-3 below for sample concentrations (converted to solids)) and the detection target was changed to IVL mRNA (the primer used was Perfect Real Time Primer (manufactured by Takara Bio Inc.)). The results are shown in Tables 2 and 3.
[0113] [Table 2]
[0114] [Table 3]
[0115] As shown in Tables 2 and 3, it was confirmed that the combined use of the fermented rice product and the Gaiyo extract or the Coix seed extract significantly improved the IVL mRNA expression promoting effect.
[0116] [Test Example 3] Loricrin (LOR) mRNA expression promoting effect test
[0117] The LOR mRNA expression promoting effect was tested in the same manner as in Test Example 1, except that the test samples were changed to rice fermentation product (Production Example 1), cockle extract (Production Example 2), aloe vera extract (Production Example 4), noni juice (Production Example 5) and coix seed extract (Production Example 6) (see Tables 4 to 7 below for sample concentrations (converted to solids)), and the detection target was changed to LOR mRNA (the primer used was Perfect Real Time Primer (manufactured by Takara Bio Inc.)). The results are shown in Tables 4 to 7.
[0118] [Table 4]
[0119] [Table 5]
[0120] [Table 6]
[0121] [Table 7]
[0122] As shown in Tables 4 to 7, it was confirmed that the LOR mRNA expression promoting effect was significantly improved by combining rice fermentation with ginger extract, aloe vera extract, noni juice, or coix seed extract.
[0123] [Test Example 4] Kallikrein 5 (KLK5) mRNA expression promoting effect test
[0124] The KLK5 mRNA expression promoting effect was tested in the same manner as in Test Example 1, except that the test samples were rice fermentation product (Production Example 1) and Spirea Extract (Production Example 2) (see Table 8 below for sample concentrations (converted to solids)) and the detection target was changed to KLK5 mRNA (the primer used was Perfect Real Time Primer (manufactured by Takara Bio Inc.)). The results are shown in Table 8.
[0125] [Table 8]
[0126] As shown in Table 8, it was confirmed that the combined use of fermented rice and Gaiyo extract significantly improved the effect of promoting KLK5 mRNA expression.
[0127] [Test Example 5] Kallikrein 7 (KLK7) mRNA expression promoting effect test
[0128] The KLK7 mRNA expression promoting effect was tested in the same manner as in Test Example 1, except that the test samples were changed to rice fermentation product (Production Example 1), cockle extract (Production Example 2) and noni juice (Production Example 5) (see Tables 9 to 10 below for sample concentrations (converted to solids)) and the detection target was changed to KLK7 mRNA (the primer used was Perfect Real Time Primer (manufactured by Takara Bio Inc.)). The results are shown in Tables 9 to 10.
[0129] [Table 9]
[0130] [Table 10]
[0131] As shown in Tables 9 to 10, it was confirmed that the combined use of fermented rice and Gaiyo extract or Noni juice significantly improved the promoting effect on KLK7 mRNA expression.
[0132] [Test Example 6] Serine peptidase inhibitor Kazal type 5 (SPINK5) mRNA expression promoting effect test
[0133] The SPINK5 mRNA expression promoting effect was tested in the same manner as in Test Example 1, except that the test samples were changed to rice fermentation product (Production Example 1), cockle extract (Production Example 2), Satsuma mandarin extract (Production Example 3), noni juice (Production Example 5) and coix seed extract (Production Example 6) (see Tables 11 to 14 below for sample concentrations (converted to solids)), and the detection target was changed to SPINK5 mRNA (the primer used was Perfect Real Time Primer (manufactured by Takara Bio Inc.)). The results are shown in Tables 11 to 14.
[0134] [Table 11]
[0135] [Table 12]
[0136] [Table 13]
[0137] [Table 14]
[0138] As shown in Tables 11 to 14, it was confirmed that the combined use of fermented rice with ume extract, satsuma mandarin extract, noni juice, or coix seed extract significantly improved the SPINK5 mRNA expression promoting effect.
[0139] [Test Example 7] Caspase 14 mRNA expression promotion test
[0140] The caspase 14 mRNA expression promoting effect was tested in the same manner as in Test Example 1, except that the test samples were changed to rice fermentation product (Production Example 1), cockle extract (Production Example 2) and noni juice (Production Example 5) (see Tables 15-16 below for sample concentrations (converted to solids)) and the detection target was changed to caspase 14 mRNA (the primer used was Perfect Real Time Primer (manufactured by Takara Bio Inc.)). The results are shown in Tables 15 to 16.
[0141] [Table 15]
[0142] [Table 16]
[0143] As shown in Tables 15 to 16, it was confirmed that the combined use of the fermented rice product and the Gaiyo extract or the Noni juice significantly improved the caspase 14 mRNA expression promoting effect.
[0144] [Test Example 8] ZO-1 mRNA expression promoting effect test
[0145] The ZO-1 mRNA expression promoting effect was tested in the same manner as in Test Example 1, except that the test samples were changed to rice fermentation product (Production Example 1), cockle extract (Production Example 2), Satsuma mandarin extract (Production Example 3), aloe vera extract (Production Example 4) and coix seed extract (Production Example 6) (see Tables 17 to 20 below for sample concentrations (converted to solids)), and the detection target was changed to ZO-1 mRNA (the primer used was Perfect Real Time Primer (manufactured by Takara Bio Inc.)). The results are shown in Tables 17 to 20.
[0146] [Table 17]
[0147] [Table 18]
[0148] [Table 19]
[0149] [Table 20]
[0150] As shown in Tables 17 to 20, it was confirmed that the combined use of rice fermentation product with ginger extract, satsuma mandarin extract, aloe vera extract or coix seed extract significantly improved the effect of promoting ZO-1 mRNA expression.
[0151] [Test Example 9] Sirtuin 1 (SIRT1) mRNA expression promoting effect test
[0152] The test samples were rice fermentation product (Production Example 1) and Spilanthes chinensis extract (Production Example 2) (see Table 21 below for sample concentrations (converted to solids)), and the detection target was changed to Sirtuin 1 (SIRT1) mRNA (the primer used was Perfect Real Time Primer (manufactured by Takara Bio Inc.)), and the SIRT1 mRNA expression promoting effect was tested in the same manner as in Test Example 1. The results are shown in Table 21.
[0153] [Table 21]
[0154] As shown in Table 21, it was confirmed that the combined use of fermented rice and Gaiyo extract significantly improved the effect of promoting SIRT1 mRNA expression.
[0155] [Test Example 10] Semaphorin 3A (Sema3A) mRNA expression promoting effect test
[0156] The test samples were changed to rice fermentation product (Production Example 1), cockle extract (Production Example 2), Satsuma mandarin extract (Production Example 3), aloe vera extract (Production Example 4) and noni juice (Production Example 5) (see Tables 22 to 25 below for sample concentrations (converted to solids)), and the detection target was changed to semaphorin 3A (Sema3A) mRNA (the primer used was Perfect Real Time Primer (manufactured by Takara Bio Inc.)), and the effect of promoting Sema3A mRNA expression was tested in the same manner as in Test Example 1. The results are shown in Tables 22 to 25.
[0157] [Table 22]
[0158] [Table 23]
[0159] [Table 24]
[0160] [Table 25]
[0161] As shown in Tables 22 to 25, it was confirmed that the combination of rice fermentation with ginger extract, satsuma mandarin extract, aloe vera extract or noni juice significantly improved the effect of promoting Sema3A mRNA expression.
[0162] [Test Example 11] Epidermal keratinocyte proliferation promotion test The epidermal keratinocyte proliferation-promoting effect of rice fermentation product (Production Example 1), cockle extract (Production Example 2), satsuma mandarin extract (Production Example 3), aloe vera extract (Production Example 4) and noni juice (Production Example 5) was tested as follows.
[0163] Normal human neonatal epidermal keratinocytes (NHEK) were cultured in normal human epidermal keratinocyte growth medium (KGM), and the cells were harvested by trypsinization. The harvested cells were collected at a concentration of 3.0 × 10 4 After diluting with KGM to a cell density of 100 cells / mL, 100 μL was seeded per well on a collagen-coated 96-well plate and cultured overnight. After culture was completed, the medium was removed and 100 μL of KGM medium containing the test sample (see Tables 26 to 29 below for sample concentration (solid content equivalent)) or KGM medium without the test sample was added to each well and cultured for 3 days.
[0164] The epidermal keratinocyte proliferation promoting effect was measured using the MTT assay. After 3 days of culture, the medium was removed, and 100 μL of MTT dissolved in PBS buffer at a final concentration of 0.4 mg / mL was added to each well. After 2 hours of culture, blue formazan produced in the cells was extracted with 100 μL of 2-propanol. After extraction, the absorbance at a wavelength of 570 nm was measured. At the same time, the absorbance at a wavelength of 650 nm was measured as turbidity, and the difference between the two was taken as the amount of blue formazan produced. From the results obtained, the epidermal keratinocyte proliferation promoting rate (%) was calculated using the following formula.
[0165] Epidermal keratinocyte proliferation promotion rate (%) = A / B x 100 Each term in the formula represents the following: A: Amount of blue formazan produced in cells to which a test sample was added B: Amount of blue formazan produced in cells without sample added The results are shown in Tables 26 to 29.
[0166] [Table 26]
[0167] [Table 27]
[0168] [Table 28]
[0169] [Table 29]
[0170] As shown in Tables 26 to 29, it was confirmed that the combined use of rice fermentation product with ginger extract, satsuma mandarin extract, aloe vera extract or noni juice significantly improved the epidermal keratinocyte proliferation-promoting effect.
[0171] [Formulation example 1] According to the composition below, a milky lotion was prepared by a conventional method. Fermented rice 0.1g Gaiyou extract 0.25g Jojoba oil 4.00g 1,3-butylene glycol 3.00g Arbutin 3.00g Polyoxyethylene cetyl ether (20E.O.) 2.50g 2.00g olive oil Squalane 2.00g Cetanol 2.00g Glyceryl monostearate 2.00g Polyoxyethylene sorbitan oleate (20E.O.) 2.00g Methyl paraoxybenzoate 0.15g Stearyl glycyrrhetinate 0.10g Phellodendron Bark Extract 0.10g Dipotassium glycyrrhizinate 0.10g Ginkgo leaf extract 0.10g Conchiolin 0.10g Phellodendron bark extract 0.10g Chamomile extract 0.10g Fragrance 0.05g Purified water Remainder (total amount is 100g)
[0172] [Formulation example 2] A cream having the following composition was prepared by a conventional method. Fermented rice 0.1g Unshu mandarin extract 0.25g Sophora root extract 0.1g Scutellaria root extract 0.1g Liquid paraffin 5.0g White beeswax 4.0g Squalane 10.0g Cetanol 3.0g Lanolin 2.0g Stearic acid 1.0g Polyoxyethylene sorbitan oleate (20E.O.) 1.5g Glyceryl monostearate 3.0g Oil-soluble licorice extract 0.1g 1,3-butylene glycol 6.0g Methyl paraoxybenzoate 1.5g Fragrance 0.1g Purified water Remainder (total amount is 100g)
[0173] [Formulation example 3] A beauty essence having the following composition was prepared by a conventional method. Fermented rice 0.1g Aloe vera extract 0.25g Chamomile extract 0.1g Carrot extract 0.1g Xanthan gum 0.3g Hydroxyethylcellulose 0.1g Carboxyvinyl polymer 0.1g 1,3-butylene glycol 4.0g Dipotassium glycyrrhizinate 0.1g Glycerin 2.0g Potassium hydroxide 0.25g Fragrance 0.01g Preservative (methyl parahydroxybenzoate) 0.15g Ethanol 2.0g Purified water Remainder (total amount is 100g)
[0174] [Formulation example 4] Tablets having the following composition were prepared by a conventional method. Fermented rice 4.0mg Noni juice (solid content) 1.0mg Dolomite (containing 20% calcium and 10% magnesium) 83.4mg Casein phosphopeptide 16.7mg Vitamin C 33.4mg Maltitol 136.8mg Collagen 12.7mg Sucrose fatty acid ester 12.0mg
[0175] [Formulation example 5] An oral liquid preparation having the following composition was produced by a conventional method. <Composition in 1 ampoule (100 mL)> Fermented rice 0.4% by mass Coix seed extract 0.1% by mass Sorbitol 12.0% by mass Sodium benzoate 0.1% by mass Fragrance 1.0% by mass Calcium sulfate 0.5% by mass Purified water remainder (100% by mass)
Claims
1. Rice yeast fermentation product, One or more selected from the group consisting of Gaiyo extract, Aloe vera extract, Noni fruit juice, Coix seed extract, and Satsuma mandarin extract; A skin barrier function improving agent characterized by having the above combination as active ingredients.
2. Rice yeast fermentation product, Gaiyou extract, A filaggrin mRNA expression promoter comprising the above combination as active ingredients.
3. Rice yeast fermentation product, Gaiyo extract and / or Yokuinin extract, 13. An involucrin mRNA expression promoter comprising the above combination as active ingredients.
4. Rice yeast fermentation product, One or more selected from the group consisting of Gaiyo extract, Aloe vera extract, Noni juice, and Coix seed extract; A loricrin mRNA expression promoter comprising the above combination as active ingredients.
5. Rice yeast fermentation product, Gaiyou extract, A kallikrein 5 mRNA expression promoter comprising the above combination as active ingredients.
6. Rice yeast fermentation product, Gaiyo extract and / or Noni juice, A kallikrein 7 mRNA expression promoter comprising the above combination as active ingredients.
7. Rice yeast fermentation product, One or more selected from the group consisting of Gaiyo extract, Noni fruit juice, Coix seed extract, and Satsuma mandarin extract; A serine peptidase inhibitor Kazal type 5 (SPINK5) mRNA expression promoter, characterized in that the above combination is contained as active ingredients.
8. Rice yeast fermentation product, Gaiyo extract and / or Noni juice, A caspase 14 mRNA expression promoter comprising the above combination as active ingredients.
9. Rice yeast fermentation product, one or more selected from the group consisting of Gaiyo extract, Aloe vera extract, Coix seed extract, and Satsuma mandarin extract; A ZO-1 mRNA expression promoter comprising the above combination as active ingredients.
10. Rice yeast fermentation product, One or more selected from the group consisting of a ginger extract, an aloe vera extract, a noni juice, and a satsuma mandarin extract; A semaphorin 3A mRNA expression promoter comprising the above combination as active ingredients.
11. Rice yeast fermentation product, One or more selected from the group consisting of a ginger extract, an aloe vera extract, a noni juice, and a satsuma mandarin extract; 2. An epidermal keratinocyte proliferation promoter comprising the above combination as active ingredients.
12. Rice yeast fermentation product, Gaiyou extract, A sirtuin 1 mRNA expression promoter comprising the above combination as active ingredients.
13. The agent according to any one of claims 1 to 12, wherein the yeast fermentation product of rice is a Saccharomyces verona fermentation product.
Citation Information
Patent Citations
Immunostimulating agent, antineoplastic agent, antiinflammatory agent, antiaging agent and skin cosmetic
JP2006056854A
Antiaging agent and epidermal keratinizing cell proliferation accelerator
JP2006316028A
External preparation for skin, for improving skin barrier function and its production method
JP2007176830A
External preparation for skin, for improving skin barrier function and its production method
JP2007176835A
Therapeutic or prophylactic agent for pruritic dermatosis
JP2008297243A
Cited By
Moisturizing and repairing fermentation composition as well as preparation method and application thereof
CN120585710A